Published in JAMA on July 28, 2004
Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys (2008) 3.61
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther (2007) 2.30
A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med (2009) 2.24
Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol (2007) 2.02
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
The central role of wear debris in periprosthetic osteolysis. HSS J (2006) 1.85
Current developments in salivary diagnostics. Biomark Med (2010) 1.83
Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol (2005) 1.59
Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. Arthritis Res Ther (2010) 1.52
Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas (2010) 1.51
Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis (2008) 1.51
Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia (2008) 1.43
A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol (2008) 1.40
Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol (2009) 1.23
Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000 (2014) 1.20
Macrophages-Key cells in the response to wear debris from joint replacements. J Biomed Mater Res A (2013) 1.18
RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med (2009) 1.17
Fatty acid consumption and risk of fracture in the Women's Health Initiative. Am J Clin Nutr (2010) 1.16
Chronic inflammation in cancer development. Front Immunol (2012) 1.14
Chronic inflammation in biomaterial-induced periprosthetic osteolysis: NF-κB as a therapeutic target. Acta Biomater (2013) 1.09
Biomaterial delivery of morphogens to mimic the natural healing cascade in bone. Adv Drug Deliv Rev (2012) 1.07
Oral inflammatory diseases and systemic inflammation: role of the macrophage. Front Immunol (2012) 1.07
Gamma interferon positively modulates Actinobacillus actinomycetemcomitans-specific RANKL+ CD4+ Th-cell-mediated alveolar bone destruction in vivo. Infect Immun (2005) 1.05
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw (2009) 1.03
Vascular calcification in middle age and long-term risk of hip fracture: the Framingham Study. J Bone Miner Res (2007) 1.02
Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis. Mol Cancer (2012) 1.02
Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis (2007) 1.00
Molecular genetic studies of gene identification for osteoporosis: the 2009 update. Endocr Rev (2010) 1.00
Abdominal aortic calcification, BMD, and bone microstructure: a population-based study. J Bone Miner Res (2008) 0.99
Denosumab: a new option in the treatment of bone metastases from urological cancers. Onco Targets Ther (2012) 0.98
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int (2010) 0.98
Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip. J Clin Endocrinol Metab (2008) 0.98
Effects of physiological variations in circulating insulin levels on bone turnover in humans. J Clin Endocrinol Metab (2011) 0.97
Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer (2006) 0.96
Skeletal metastasis: treatments, mouse models, and the Wnt signaling. Chin J Cancer (2013) 0.95
Oophorectomy-induced bone loss is attenuated in MAGP1-deficient mice. J Cell Biochem (2012) 0.94
Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes. Cell Mol Life Sci (2010) 0.94
Relationship between serum RANKL and RANKL in bone. Osteoporos Int (2011) 0.94
Microfibril-associated glycoprotein-1, an extracellular matrix regulator of bone remodeling. J Biol Chem (2010) 0.94
The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta. J Orthop Res (2008) 0.93
Genetic variation and reproductive timing: African American women from the Population Architecture using Genomics and Epidemiology (PAGE) Study. PLoS One (2013) 0.93
Aromatase inhibitors and bone loss. Oncology (Williston Park) (2006) 0.92
Oral mucosal dendritic cells and periodontitis: many sides of the same coin with new twists. Periodontol 2000 (2007) 0.92
Increased bone resorption is associated with increased risk of cardiovascular events in men: the MINOS study. J Bone Miner Res (2009) 0.92
TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. PLoS One (2013) 0.91
Association between lumbar bone mineral density and vascular stiffness as assessed by pulse wave velocity in postmenopausal women. J Bone Miner Metab (2008) 0.91
Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study. Osteoporos Int (2010) 0.91
Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90
Arterial calcifications. J Cell Mol Med (2010) 0.90
The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies. Clin Cases Miner Bone Metab (2013) 0.90
Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility. Ther Clin Risk Manag (2012) 0.90
Mechanisms of ectopic calcification: implications for diabetic vasculopathy. Cardiovasc Diagn Ther (2015) 0.89
Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging (2013) 0.89
Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options. Can Urol Assoc J (2010) 0.89
Interleukin-10 inhibits gram-negative-microbe-specific human receptor activator of NF-kappaB ligand-positive CD4+-Th1-cell-associated alveolar bone loss in vivo. Infect Immun (2006) 0.89
Osteoclast activators are elevated in intervertebral disks with Modic changes among patients operated for herniated nucleus pulposus. Eur Spine J (2015) 0.89
Osteoprotegerin Lys3Asn polymorphism and the risk of fracture in older women. J Clin Endocrinol Metab (2008) 0.88
Osteoporosis in juvenile idiopathic arthritis--a practical approach to diagnosis and therapy. Eur J Pediatr (2007) 0.88
The association of red blood cell n-3 and n-6 fatty acids with bone mineral density and hip fracture risk in the women's health initiative. J Bone Miner Res (2013) 0.88
Targeting bone remodeling by isoflavone and 3,3'-diindolylmethane in the context of prostate cancer bone metastasis. PLoS One (2012) 0.87
Osteoporosis: New-Generation Drugs. Breast Care (Basel) (2010) 0.87
Estrogenic side effects of androgen deprivation therapy. Rev Urol (2007) 0.87
Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis. Biomed Res Int (2014) 0.86
Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications. Springerplus (2013) 0.86
Pharmacological management of osteogenesis. Clinics (Sao Paulo) (2014) 0.85
Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study. Osteoporos Int (2008) 0.85
Biomarkers of vascular calcification and mortality in patients with ESRD. Clin J Am Soc Nephrol (2014) 0.85
Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther (2008) 0.84
Ovariectomy increases vascular calcification via the OPG/RANKL cytokine signalling pathway. Eur J Clin Invest (2008) 0.83
The role of osteocytes in targeted bone remodeling: a mathematical model. PLoS One (2013) 0.83
TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women. Menopause (2010) 0.83
High-frequency, low-magnitude vibration does not prevent bone loss resulting from muscle disuse in mice following botulinum toxin injection. PLoS One (2012) 0.83
Role of bone mineral density in the inverse relationship between body size and aortic calcification: results from the Baltimore Longitudinal Study of Aging. Atherosclerosis (2014) 0.83
Role of macrophages in the biological reaction to wear debris from joint replacements. J Long Term Eff Med Implants (2014) 0.82
Electroacupuncture at the governor vessel and bladder meridian acupoints improves postmenopausal osteoporosis through osteoprotegerin/RANKL/RANK and Wnt/β-catenin signaling pathways. Exp Ther Med (2015) 0.82
Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts. Acta Vet Scand (2011) 0.82
Blood biomarkers of osteoporosis in mild cognitive impairment and Alzheimer's disease. J Neural Transm (Vienna) (2009) 0.82
Reciprocal cross-talk between Prostaglandin E2 and bone in prostate cancer: a current review. Cent European J Urol (2011) 0.82
Expression and regulation of osteoprotegerin in adipose tissue. Yonsei Med J (2007) 0.82
Osteoprotegerin as a marker of atherosclerosis in diabetic patients. Int J Endocrinol (2013) 0.82
Metabolomic profiles delineate signature metabolic shifts during estrogen deficiency-induced bone loss in rat by GC-TOF/MS. PLoS One (2013) 0.82
Involvement of SOCS3 in regulation of CD11c+ dendritic cell-derived osteoclastogenesis and severe alveolar bone loss. Infect Immun (2009) 0.81
Fructus Ligustri Lucidi (FLL) ethanol extract increases bone mineral density and improves bone properties in growing female rats. J Bone Miner Metab (2013) 0.81
Pathogenesis of Metastatic Calcification and Acute Pancreatitis in Adult T-Cell Leukemia under Hypercalcemic State. Leuk Res Treatment (2011) 0.81
Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. Osteoporos Int (2007) 0.81
The Association between Metabolic Syndrome, Bone Mineral Density, Hip Bone Geometry and Fracture Risk: The Rotterdam Study. PLoS One (2015) 0.81
Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis. Ther Adv Musculoskelet Dis (2015) 0.81
Calcium metabolism and vitamin D in the extreme longevity. Exp Gerontol (2007) 0.81
A systematic review of omega-3 fatty acids and osteoporosis. Br J Nutr (2012) 0.81
A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer. BMC Cancer (2008) 0.81
Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss? Osteoporos Int (2005) 0.81
Semen Astragali Complanati- and Rhizoma Cibotii-enhanced bone formation in osteoporosis rats. BMC Complement Altern Med (2013) 0.80
High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. J Bone Miner Metab (2009) 0.80
Pulsed electromagnetic fields improve bone microstructure and strength in ovariectomized rats through a Wnt/Lrp5/β-catenin signaling-associated mechanism. PLoS One (2013) 0.80
Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol (2010) 0.80
OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOST. J Mol Histol (2007) 0.80
Calcium and vitamin D supplementation through fortified dairy products counterbalances seasonal variations of bone metabolism indices: the Postmenopausal Health Study. Eur J Nutr (2010) 0.80
Bone-targeted agents: preventing skeletal complications in prostate cancer. Urol Clin North Am (2012) 0.80
Bone health and associated metabolic complications in neuromuscular diseases. Phys Med Rehabil Clin N Am (2012) 0.80
Mineral surface in calcified plaque is like that of bone: further evidence for regulated mineralization. Arterioscler Thromb Vasc Biol (2008) 1.29
Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum (2009) 1.27
Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol (2009) 1.23
The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant (2008) 1.11
Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation (2003) 1.09
TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J Biol Chem (2008) 1.09
Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis (2005) 1.02
Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab (2004) 1.02
The role of osteoclast-associated receptor in osteoimmunology. J Immunol (2011) 0.97
Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett (2009) 0.97
Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway. J Bone Miner Res (2008) 0.95
Parvovirus B19 genome in endomyocardial biopsy specimen. Circulation (2004) 0.93
TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. PLoS One (2013) 0.91
Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. Thromb Haemost (2006) 0.91
Acute parvovirus B19 infection associated with myocarditis in an immunocompetent adult. Hum Pathol (2003) 0.90
Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem (2009) 0.88
17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7. Biochem Biophys Res Commun (2008) 0.87
Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol (Oxf) (2004) 0.87
Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease. J Clin Endocrinol Metab (2002) 0.84
Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. J Bone Miner Res (2013) 0.84
The osteoclast-associated receptor (OSCAR) is a novel receptor regulated by oxidized low-density lipoprotein in human endothelial cells. Endocrinology (2011) 0.84
Endocrine and clinical correlates of myostatin serum concentration in men--the STRAMBO study. J Clin Endocrinol Metab (2012) 0.84
Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. J Bone Miner Res (2005) 0.83
Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc Res (2011) 0.83
Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J Cell Biochem (2005) 0.80
Lipids in biocalcification: contrasts and similarities between intimal and medial vascular calcification and bone by NMR. J Lipid Res (2012) 0.80
Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in heterotopic vascular ossification. Thromb Haemost (2005) 0.79
Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions. Clin Biochem (2011) 0.79
Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. J Cell Biochem (2002) 0.79
Monocytic expression of osteoclast-associated receptor (OSCAR) is induced in atherosclerotic mice and regulated by oxidized low-density lipoprotein in vitro. Biochem Biophys Res Commun (2013) 0.78
Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med (2002) 0.76
Matrix metalloproteinases and their inhibitors in malignant and autoreactive pericardial effusion. Am J Cardiol (2005) 0.76
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 0.75
NT5E mutations and arterial calcifications. N Engl J Med (2011) 0.75
DKK1 in multiple myeloma. N Engl J Med (2004) 0.75
Calcification inhibitors in vascular calciphylaxis associated with normal renal function. Thromb Haemost (2012) 0.75